WordNet

any compound that contains water of crystallization
become hydrated and combine with water
cause to be hydrated; add water or moisture to; "hydrate your skin"
supply water or liquid to in order to maintain a healthy balance; "the bicyclists must be hydrated frequently"
small tubular solitary freshwater hydrozoan polyp
trouble that cannot be overcome by a single effort because of its many aspects or its persistent and pervasive quality; "we may be facing a hydra that defies any easy solution"

PrepTutorEJDIC

含水化合物,水化物 / 〈化合物〉‘を'水和させて水化物を作る

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 多発性骨髄腫：免疫調節薬（サリドマイド、レナリドミド、ポマリドミド）を投与している患者の静脈血栓塞栓症予防multiple myeloma prevention of venous thromboembolism in patients receiving immunomodulatory drugs thalidomide lenalidomide and pomalidomide [show details]
…patients with MM taking single-agent lenalidomide does not appear to be increased over that of patients with MM not taking lenalidomide. In contrast, the use of lenalidomide in combination with high dose glucocorticoids …
2. 非プラチナ製剤による従来のがん化学療法における神経学的合併症の概要overview of neurologic complications of conventional non platinum cancer chemotherapy [show details]
…dexamethasone plus either lenalidomide or placebo for relapsed or refractory multiple myeloma , the rate of grade 3 peripheral neuropathy was only 1.4 percent among patients treated with lenalidomide versus 0.6 percent …
3. 多発性骨髄腫：症状を伴う場合に行う初期化学療法の選択肢multiple myeloma selection of initial chemotherapy for symptomatic disease [show details]
…nine months of induction with either KRd or bortezomib, lenalidomide, and dexamethasone (VRd), each followed by a second randomization to lenalidomide maintenance given for either two years or until disease …
4. 低リスクの骨髄異形成症候群の治療treatment of lower risk myelodysplastic syndromes mds [show details]
…dose lenalidomide (10 mg daily on days 1 to 21), lower dose lenalidomide (5 mg daily on days 1 to 28), or placebo, each delivered in a 28-day cycle. For low dose lenalidomide, lower dose lenalidomide, and …
5. 多発性骨髄腫：再発・難治性の多発性骨髄腫への治療レジメンmultiple myeloma regimens used for relapsed or refractory disease [show details]
…additional combinations such as bendamustine, lenalidomide, and dexamethasone, and panobinostat, lenalidomide, and dexamethasone . The combination of lenalidomide, low-dose oral cyclophosphamide, and prednisone …

English Journal

Gateways to clinical trials.

Tomillero A, Moral MA.
Methods and findings in experimental and clinical pharmacology.Methods Find Exp Clin Pharmacol.2009 Dec;31(10):661-700.
[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human growth hormone, Aliskiren fumarate, AMG-221, Amlodipine besylate/olmesartan medoxomil, Aprepitant; Bavituximab, Bevacizumab, Bexarotene, BIBW-2992, BMS-690514, Bortezo
PMID 20140276

Gateways to clinical trials.

Tomillero A, Moral MA.
Methods and findings in experimental and clinical pharmacology.Methods Find Exp Clin Pharmacol.2009 Nov;31(9):597-633.
Abacavir sulfate/lamivudine, Adalimumab, AdCD40L, Adefovir, Adefovir dipivoxil, Ambrisentan, Amlodipine, Amlodipine besylate/olmesartan medoxomil, AN-2728, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride, Atrasentan, Azacitidine, Bevacizumab, Blinatumomab, Bortezom
PMID 20094643

Gateways to clinical trials.

Tomillero A, Moral MA.
Methods and findings in experimental and clinical pharmacology.Methods Find Exp Clin Pharmacol.2009 May;31(4):263-98.
(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG-317, Amlodipine, Aripiprazole, Atazanavir sulfate, Azacitidine; Becatecarin, Belinostat, Bevacizumab, BMS-387032, BMS-690514, Bortezomib; Casopitant mesylate, Cetuximab, Cho
PMID 19557204